🇺🇸 FDA
Pipeline program

OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab/Relatlimab

CA224-047

Phase 3 small_molecule active

Quick answer

OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab/Relatlimab for Previously Untreated Metastatic or Unresectable Melanoma is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bristol-Myers Squibb / Pfizer EEIG
Indication
Previously Untreated Metastatic or Unresectable Melanoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials